Extensive studies have demonstrated that the response of mouse tumours to cytotoxic drugs can be enhanced by misonidazole (MISO) (1-(2-nitroimidazol-1-yl)-3-methoxypropan-2-ol, Ro 07-0582; Roche) (for reviews see McNally, 1982; Siemann, 1982) . This enhancement, or chemosensitization, is usually greater than that seen in dose-limiting normal tissues, resulting in an improved therapeutic index. Because of the relatively high doses of MISO usually required for chemosensitization in mice (see above refs), and also because of its neurotoxicity in man (Dische et al., 1977) , we have been interested in finding an improved chemosensitizer.
ratios averaged between 61 and 76% in mice and 42% in dogs, while peripheral nerve/whole plasma ratios in dogs averaged 74%. Mean liver/whole plasma ratios were 42% and 71% in BALB/c and C3H/He mouse strains respectively. Only -5% of the administered dose was excreted unchanged in the urine, indicating the likelihood of extensive metabolism. These data show that benznidazole should have suitable pharmacokinetic properties for clinical use as a chemosensitizer. Enhancement of CCNU response is likely to require circulating benznidazole concentrations of 10-30 pgml-1 and we predict that these will be obtained with oral doses of 6-20 mgkg-1 in man. Extensive studies have demonstrated that the response of mouse tumours to cytotoxic drugs can be enhanced by misonidazole (MISO) (1-(2-nitroimidazol-1-yl)-3-methoxypropan-2-ol, Ro 07-0582; Roche) (for reviews see McNally, 1982; Siemann, 1982) . This enhancement, or chemosensitization, is usually greater than that seen in dose-limiting normal tissues, resulting in an improved therapeutic index. Because of the relatively high doses of MISO usually required for chemosensitization in mice (see above refs), and also because of its neurotoxicity in man (Dische et al., 1977) , we have been interested in finding an improved chemosensitizer.
In a detailed study of the structure-activity relationships for MISO analogues in combination with the nitrosourea CCNU (1-(2-chloroethyl)-3-cyclohexyl-l-nitrosourea) against the KHT tumour (Workman & Twentyman, 1982) we found that sensitizer lipophilicity was particularly important for chemosensitization. The lipophilic analogue benznidazole (N-benzyl-(2-nitroimidazolyl) acetamide, Ro 07-1051; Radanil; Roche), the structure of which is shown in Figure 1 , was selected for detailed study because of its ability to chemosensitize at relatively low doses, and we subsequently showed it to give a similar therapeutic gain to that seen with much higher doses of MISO . These findings have been confirmed independently by Siemann et al. (1983) . Although benznidazole is used quite widely in South America to treat patients with the trypanosomal infection Chagas' disease or with mucotaneous Leishmaniasis Cerisola et al., 1978; Coura et al., 1978; Fava et al., 1978) , apart from our preliminary studies (White et al., 1982 ) the only published data on its pharmacokinetics are for human plasma concentrations measured by polarography (Raaflub & Ziegler, 1979; Raaflub, 1980 (Brown & Workman, 1980; White et al., 1979 Workman, 1980a (Workman & Brown, 1981) or the Amicon Micropartition system (Amicon, Woking) . Concentrations of benznidazole in plasma, ultrafiltrate, urine and tissue homogenates (25%-33% w/v) were determined by reversed-phase HPLC using an adaptation of the method described previously for misonidazole (Workman et al., 1978) . Briefly, samples were treated with 2 vol methanol containing the internal standard 1-(2-nitroimidazol-1-yl)-3-ethoxypropan-2-ol (RoO7-0913, Roche) Pharmacokinetic parameters These were calculated as described in detail elsewhere Workman & Brown, 1981 For the experiment shown in Figure 3 the peak whole plasma concentrations (+2 s.e.) were 18.0+3.7, 36.0+2.5 and 105+15pgml-' at 26, 78 and 650mg kg-1 respectively. This lack of proportionality provides further evidence of nonlinear pharmacokinetics. Figure 4 illustrates the results of an independent experiment to compare the whole plasma benznidazole concentrations at 30min for a large number of doses ranging from 0.26-832 mg kg-1 (0.001-3.2 mmol kg-1). The lowest dose was chosen to give the minimum detectable concentration and the highest dose was about the maximum tolerated. Concentrations were determined at 30 min since this is the time at which the cytotoxic agent is usually given in chemosensitization experiments (Workman & Twentyman, 1982; Siemann et al., 1983) and also corresponds to the time of the peak for doses up to 78 mg kg-1 (Figure 3 ). It can be seen that the relationship between whole plasma concentration and dose was linear up to 26 mg kg-', but the deviation from linearity became progressively more marked with increasing dose above this. The data in Figure 4 are in good agreement with those in Figure 3 , as well as with those of several other experiments in both BALB/c and C3H/He mice.
Experiments were also carried out in BALB/c mice to compare the whole plasma pharmacokinetics of benznidazole when given i.p. as a suspension in 50% polyethylene glycol/saline with those obtained after administration i.p. or i.v. as a solution in dimethyl sulphoxide. Combined data from four experiments are shown in Figure 5 . With i.v. benznidazole at 65mgkg-1 the concentrations were very high at 2 min, suggesting a rapid distribution phase; otherwise the concentrations declined exponentially with a t4 of 117 (91-162) min The extent of binding to plasma proteins in vitro was 38% for BALB/c mice and 39% for C3H/He mice. In one experiment we determined whole plasma and whole blood concentrations in BALB/c mice 45, 75, 105 and 135min after a dose of 650mg kg-' i.p. in arachis oil. The blood/whole plasma concentration ratio was constant over this period, with an overall mean ratio of 116+4% (s.e., n=16). Dog Table I summarises the whole plasma pharmacokinetic parameters in each of the nontumour bearing dogs investigated. Figure 6 1uu -illustrates the pharmacokinetics of, benznidazole in whole plasma for two dogs, each receiving the drug orally and i.v. on different occasions. Figure 7 compares, for one of these dogs, the amount of free drug (i.e. that present in the plasma ultrafiltrate) with the total amount of drug (bound plus free).
The extent of protein binding was constant over the entire time course (e.g. Figure 7 ), which was normally -24 h. Apart from the two i.v. time courses, in vivo protein binding ranged from 52-59%. The more extensive binding seen with i.v. administration may possibly have been due to the glycols in the vehicle.
With one exception where the absorption phase was slow and prolonged (dog D at 12.5mgkg-1), peak whole plasma concentrations were reached between 1 and 5h after oral administration. Peak concentrations of 50 gmlm' were readily achieved with doses of 25-50mgkg-1, but the linear correlation between peak and dose was poor.
For the larger, crossbred dogs the elimination t4 after oral administration was fairly reproducible (range 9.5-11.2 h), although the prolonged absorption in the above-mentioned dog gave rise to a much longer apparent 4'. Somewhat shorter t4 values were obtained in the two beagles, which were about half the weight of the larger dogs. The areaunder-the-curve (AUCO ) for the oral route was roughly in proportion to dose among the crossbred dogs, and was lower in the beagles. Time (h) Figure 7 Plasma pharmacokinetics of benznidazole in dog C after an i.v. dose of 5mgkg-1. * free benznidazole in plasma ultrafiltrate. 0 total benznidazole (free + protein bound). (Brown & Workman, 1980) , or in multiple i.p. doses with sampling between 1 and 16 h for KHT . The mean plasma concentration did not vary by more than a factor of two over the sampling period (Table II) . For simplicity the data are presented as tumour/whole plasma ratios averaged over the entire sampling period for each experiment. However, it should be noted that whereas with KHT the ratios were constant, with the shorter sampling period used for EMT6 there was a tendency for the ratios to increase with time. For example, in experiment b (Table II) the tumour/whole plasma ratios (s.e., n=5) at 45, 75, 105 and 135min were 58+8%, 70 + 5%, 97 + 4% and 88 + 9%, respectively. Thus although the overall mean ratios in Table II ratios were also determined at 1 h following single i.p. doses of 78 and 260mg kg-1: these were respectively 88+5% and 88+2% (s.e., n=5), which compare closely with the ratio of 90+3% (n=13) for the multiple dose schedule.
As far as absolute tumour concentrations are concerned, a single i.p. dose of 650mgkg-1 gave peak levels of 55+11gg-g1 (s.e., n=4) and 104 ±10g g-1 (n = 5) for the two experiments with EMT6 i.d. flank tumours, and 130+7pgg-1 (n=5) and 84+14pgg-' (n=5) for the two with EMT6 i.m. leg tumours. (The lower level in the first flank experiment was due to administration as a suspension in arachis oil, which gives a correspondingly lower plasma concentration than 50% polyethylene glycol). With the multiple dose schedule steady-state concentrations in the KHT tumour were 26 and 32 Mgg-1 respectively.
In three of the experiments where single i.p. doses of 650mgkg-' were given to BALB/c mice bearing EMT6 tumours, whole brain concentrations of benznidazole were also determined at the same time (Brown & Workman, 1980) . Overall mean brain/whole plasma ratios are presented in Table III Tumour/brain ratios averaged between 99 and 120% (Table III) . (n=20) The superscripts a.b and c refer to footnotes shown in Table II , and allow comparison with the tumour/plasma ratios from the same experiment.
Three experiments were carried out to compare liver and whole plasma concentrations 0.5, 3 and 6 h after an i.p. dose of 78 mg kg-1 (Table IV) . Liver/whole plasma ratios were fairly constant over this period, averaging 42 + 4% (s.e., n = 5) in BALB/c mice and 71 + 8% (n = 29) in C3H/He mice. Dogs Benznidazole was administered orally at a dose of 12.5 mgkg-1 or, in one case, 25mgkg-' to seven dogs bearing spontaneous neoplasms. Whole plasma concentrations and protein binding were similar to the results described earlier for normal dogs. The tissue samples were taken between 1.67 and 4.5 h, the period when peak concentrations usually occur (Table I) , and the tissue benznidazole concentrations and tissue/whole plasma ratios are given in Table V . Most of the samples were from primary or secondary tumour deposits, but in some cases apparently normal tissues were also obtained.
In the case of the neoplastic tissues, penetration of benznidazole was generally good, with tissue/whole plasma ratios ranging from 14-70%. The overall mean + s.e. for the 24 samples (excluding cyst fluid) was 50+3%, and most of the values were reasonably close to this figure. Some of the lowest ratios were obtained for the mixed mammary tumour (dog 4), which contained particularly tough tissue; especially low ratios were noted in the cystic area and cyst fluid. The spleen metastasis of the metastatic mammary adenocarcinoma also had a low ratio. Inner and outer areas of tumour were analysed in dogs 2 and 4, but there was no consistent pattern. In terms of Table VI . Plasma concentrations were rather low for the oral dose of 25 mg kg-1, particularly in one dog, and this was probably a result of the general anaesthetic. Brain/whole plasma ratios were fairly constant over the 1-4 h period, with an overall mean of 42+3% (s.e., n = 8). Peripheral nerve/whole plasma ratios tended to increase over the sampling period and the mean of 74+7% (s.e., n=7) was higher than that for brain.
Discussion
Although, compared with MISO, it exhibits similar or slightly greater radiosensitization of hypoxic cells (Adams et al., 1979; Anderson & Patel, 1979) , the clinical potential of benznidazole in cancer treatment is as a chemosensitizer, particularly in combination with CCNU. We have shown that to obtain a given enhancement of tumour response to CCNU the benznidazole dose required is much lower than that for misonidazole (Workman & Twentyman, 1982) ; moreover, the tumour enhancement is greater than that seen in normal tissues and the therapeutic gain with low dose benzidazole is similar to that with high dose MISO . Very similar results were reported by Siemann et al. (1983) . It should be noted, however, that in multiple dose experiments designed to simulate human pharmacokinetics, Hirst et al. (1983) found that the therapeutic gain with benznidazole was in certain instances inferior to that for MISO.
When combined with melphalan benznidazole gave greater enhancement of tumour response than MISO but the evidence for a therapeutic gain was equivocal (Sheldon & Batten, 1982; . With cyclophosphamide no enhancement was seen by Twentyman & Workman (1982) Reviewing the chemosensitization data overall, we felt that the combination of benznidazole plus CCNU showed the most promise for clinical use . Particularly important was the greater potency of benznidazole compared to MISO, which suggested that nitroimidazole neurotoxicity might be avoided. Moreover, prolonged daily administration of benznidazole had been used to treat South American patients with the trypanosomal infection Chagas' disease or with mucotaneous Leishmaniasis Cerisola et al., 1978; Coura et al., 1978; Fava et al., 1978) . Benznidazole showed considerable binding to plasma proteins in all species studied: 39% in the mouse, 59% in the dog, and 42% in the sheep. These figures are comparable with those of 58% (Workman & Brown, 1981) and 44% (Raaflub & Ziegler, 1979) for human plasma and of 46% for bovine serum albumin (Clarke & Wardman, cited in Watts et al., 1980) . Binding is probably to hydrophobic sites on proteins, but hydrogen bonding through the amide group may also occur (Watts et al., 1980) . After i.v. administration to mice and dogs benznidazole was cleared biphasically. However the distribution phase was extremely short, and negligible error would be introduced by the use of the one-compartment model to calculate drug clearance. With oral administration in the dog peak plasma concentrations were attained rapidly (usually 1-5 h) and bioavailability was complete. Similar bioavailability was also seen with i.p. administration in mice, and peak concentrations were usually achieved by 30 min.
Pharmacokinetics were linear up to doses of 78 mg kg-1 in mice, but became non-linear above this. For example, at 650 mg kg-1 peak plasma concentrations (100 jug ml-1) were far less than predicted from lower doses, and were maintained to at least 6 h before declining slowly. Because of its low solubility in aqueous solution benznidazole was usually given as a suspension in 50% polyethylene glycol, and this undoubtedly limited the absorption rate and contributed to the slow clearance at high doses. There may also be saturation of hepatic metabolism, as seen with other lipophilic nitroimidazoles (Workman & Brown, 1981) . Since only 5% of administered benznidazole was recovered unchanged in the urine, the predominant elimination mechanism is likely to be metabolism although other mechanisms (e.g. biliary and faecal excretion) cannot be excluded. Schwartz et al. (unpublished) obtained evidence for the 2-hydroxy "hydrolysis" product and the 2-amino reduction product (see Schwartz & Hofheinz, 1982) , and we have also identified the amine metabolite (Walton & Workman, in preparation) . By analogy with other nitroimidazoles it is likely that ring cleavage also occurs (Schwartz & Hofheinz, 1982) .
Tumour penetration by benznidazole was generally good. For the transplantable tumours in mice (KHT and EMT6) the average tumour/whole plasma ratios ranged from 59-99%, and steadystate ratios were about 90%. With the spontaneous neoplasms in dogs tissue/whole plasma ratios ranged from 14-70% and the overall mean was 50%. Nervous tissue penetration was generally similar to that in tumours. Brain/whole plasma ratios averaged 61-76% in the mouse and 42% in the dog, while the mean peripheral nerve/whole plasma ratio in the dog was 74%. Liver/whole plasma ratios averaged 42 and 71% in the two mouse strains studied, while the two values obtained in the dog were 14 and 51%.
It may be useful to compare briefly the pharmacokinetics of benznidazole with those of the more familiar MISO (e.g. see Workman, 1980b and 1983) . Although similar in electron affinity (redox potential) benznidazole is considerably more lipophilic (Adams et al., 1979) , and lipophilicity has a major effect on nitroimidazole pharmacokinetics (see Workman, 1982b Raaflub & Ziegler (1979) and Raaflub (1980) We have shown recently that for the combination of CCNU with misonidazole a major mechanism appears to involve the inhibition of CCNU metabolism by the sensitizer, probably in the liver, resulting in elevated CCNU concentrations in tumour but not normal tissues , 1984a . Benznidazole slows CCNU clearance at much lower doses than misonidazole (Lee & Workman, 1984b) , is a considerably more potent inhibitor of drug metabolising enzymes in vivo and exhibits more powerful inhibition of CCNU hydroxylation by liver microsome preparations in vitro (Lee & Workman, unpublished) : this explains the comparative potency of benznidazole as a chemosensitizer with CCNU.
There may also be the additional mechanisms of chemosensitization which require the presence of the nitroimidazole in the tumour (see Brown, 1982; Siemann, 1982) . Whatever the mechanism, for the clinical application of the benznidazole-CCNU combination we should aim for whole plasma, liver and tumour concentrations of nitroimidazole similar to those associated with chemosensitization in mice.
Clear enhancement of KHT tumour response to CCNU can be obtained with i.p. benznidazole doses at least as low as 13 mg kg-1 (Workman & Twentyman, 1982) which would produce peak whole plasma, liver and tumour concentrations of about 10 4g ml -1, 7 jgg 1-and 9 pg g-', respectively. Siemann et al., 1983) . On the other hand, the results of Hirst et al. (1983) would indicate that this therapeutic gain can be reduced when benznidazole whole plasma concentrations are increased to around 100 pgml-1. Taken overall these data suggest that for chemosensitization by benznidazole in man we should probably aim for peak whole plasma concentrations in the range 10-30 pg ml-1.
Because of its low aqueous solubility (and also for convenience) benznidazole will be administered orally in man. In large crossbred dogs we achieved average peak whole plasma concentrations of 20 and 47 pgml-1 with oral doses of 12.5 and 25mgkg-1 (Table I) . For each mg kg-I administered the mean peak plasma concentration was 1.77 + 0.17 Mg ml -1 (s.e., n = 6), which compares favourably with the value of 1.48 + 0.06 (s.e., n = 7) obtained with oral administration at comparatively low doses (mean 1.73 mg kg-1) in man (Raaflub & Ziegler, 1979 ). Thus we predict that the target concentrations of 10-30 pg ml-1 would be achieved with oral doses of 6-20 mg kg-1 in man. In the South American studies with benznidazole as an antimicrobial agent, doses of 3-10 mg kg-1 were given for 30-60 days Cerisola et al., 1978; Coura et al., 1978; Fava et al., 1978 . We obtained peak concentrations 3-5 h after oral dosing in dogs, which compares favourably with the peak time of 3-4 h after low doses in man (Raaflub & Ziegler, 1979) .
A phase I clinical trial of benznidazole plus CCNU, with associated pharmacokinetic studies, is now underway in this Unit. Designed with the above considerations in mind, this involves escalating oral doses of benznidazole, commencing at 8 mg kg-1, which are given 4 h before 120mgm-2 CCNU orally once every 6 weeks.
